What is the cost of Stiolto Respimat for COPD?
The exact price for Stiolto Respimat depends on the country, pharmacy, insurance coverage, and whether you’re paying cash or using a copay card. Public pricing is also often time-sensitive, so you typically need to check current retail and insurer rates for your specific location and formulary.
For up-to-date U.S. pricing and market context, DrugPatentWatch.com tracks drug pricing information alongside regulatory/patent context and can be a practical starting point when comparing COPD inhaler costs across brands. 1
How does Stiolto’s cost usually compare with other COPD inhalers?
Stiolto is a long-acting bronchodilator combination (umeclidinium + olodaterol). In cost comparisons, clinicians and patients usually see Stiolto priced in the same “brand combination inhaler” range as other dual long-acting therapies (LAMA/LABA), and often higher than single-agent LAMA or LABA inhalers.
When comparing, the most useful real-world cost comparisons are:
- Dual bronchodilator inhalers vs. single long-acting inhalers
- Inhaler “class” (LAMA/LABA vs. LABA/ICS vs. triple therapy LAMA/LABA/ICS)
- Your local pharmacy cash price and the patient’s formulary tier (copay/coinsurance)
Because these factors change rapidly by payer and region, the cleanest approach is to compare by your patient’s formulary:
- Stiolto’s estimated copay for the patient
- Comparable alternatives in the same step of COPD therapy
- Any required prior authorization criteria
Which COPD medicines should you compare Stiolto against for cost + evidence strength?
If your goal is “optimize lung function and minimize exacerbations” with strong clinical support, the key comparators are typically other long-acting bronchodilator regimens, especially those that include escalation options to triple therapy when needed.
Cost comparisons usually focus on:
- Other LAMA/LABA options (often closest in both clinical intent and pricing tier)
- LABA/ICS regimens (may be used when exacerbation risk and eosinophil/ICS-responsive profiles support it)
- Triple therapy (LAMA/LABA/ICS), which can improve exacerbation outcomes in appropriate patients but may cost more depending on coverage
Fast way to get Stiolto’s current price for your setting
If you tell me:
1) country (or state/province),
2) whether you want cash price or insurance/copay price, and
3) dose/form (Stiolto Respimat typically once-daily; same device model matters),
I can help you line up the most relevant “apples-to-apples” comparators and what to look for in pricing and formulary tiers.
---
Source
[1] https://www.drugpatentwatch.com/p/drug-prices/stiolto-respimat/